---
title: "Bombay HC: FDA Actions Disproportionate, Urges Restraint"
url: https://projectchintan.com/article/bombay-hc-tells-fda-exercise-restraint-in-actions-6lk6e
publisher: Project Chintan
author: Project Chintan Newsroom
section: India
published: 2026-08-11T21:00:37.048Z
modified: 2026-08-11T23:45:11.704Z
language: en-IN
---

# Bombay HC: FDA Actions Disproportionate, Urges Restraint

The Bombay High Court cautioned the Maharashtra FDA against overreach, likening their actions to using a "sword to kill a mosquito." The court directed the FDA to provide hearings before taking punitive measures against pharmaceutical companies.

## Key takeaways

- The Bombay High Court criticized the Maharashtra FDA for excessive regulatory actions.
- The court mandated that the FDA must provide hearings to companies before taking punitive measures.
- Cadila Pharmaceuticals challenged a FDA order that halted medicine sales and led to stock seizure.
- The FDA agreed to withdraw its order and provide a hearing to Cadila Pharmaceuticals.

## What Happened

The Bombay High Court has directed the Maharashtra Food and Drug Administration (FDA) to grant pharmaceutical companies a hearing before initiating action against their products. The court observed that the regulator was employing excessive force, likening their approach to using a "sword to kill a mosquito."

A Division Bench, comprising Acting Chief Justice Ravindra Ghuge and Justice Gautam Ankhad, made these remarks while adjudicating a case filed by Cadila Pharmaceuticals Limited. The company challenged the FDA's decision to halt the sale and distribution of certain medicines and seize stock valued at ₹2.45 crore across Maharashtra due to perceived branding similarities.

## Key Facts

- The Bombay High Court directed the Maharashtra FDA to provide hearings before taking action against pharmaceutical companies.

- The court characterized the FDA's actions as using a "sword to kill a mosquito."

- Cadila Pharmaceuticals Limited filed a petition challenging the FDA's order to ban the sale and distribution of its medicines and seize stock worth ₹2.45 crore.

- The FDA's action was reportedly due to branding similarities and was described as a preventive measure by the government pleader.

- The FDA agreed to revoke its orders against Cadila Pharmaceuticals, issue show-cause notices, and grant a hearing before issuing a reasoned order.

- The High Court accepted the government pleader's statement and disposed of the petition.

- The High Court warned of imposing costs on the FDA, noting a pattern of similar actions by the regulator.

## Background

The case involved Cadila Pharmaceuticals Limited challenging the FDA's move to stop its products and seize inventory over branding similarities. The government pleader stated that the decision was a preventive measure amid confusion between the medicines.

## Why It Matters

The High Court's intervention highlights concerns about regulatory overreach and the need for due process. The court's strong remarks suggest a pattern of disproportionate action by the FDA, emphasizing that regulatory power must be exercised with restraint and proper procedure, even in cases of alleged minor infractions.

---
Canonical: https://projectchintan.com/article/bombay-hc-tells-fda-exercise-restraint-in-actions-6lk6e
Reported from: Multiple Sources